Boston Trust Walden Corp Buys 4,920 Shares of Medpace Holdings, Inc. (NASDAQ:MEDP)

Boston Trust Walden Corp raised its stake in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 3.8% in the 4th quarter, according to its most recent disclosure with the SEC. The firm owned 134,575 shares of the company’s stock after purchasing an additional 4,920 shares during the period. Boston Trust Walden Corp’s holdings in Medpace were worth $44,710,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of the stock. Pallas Capital Advisors LLC grew its stake in shares of Medpace by 179.7% during the 4th quarter. Pallas Capital Advisors LLC now owns 3,270 shares of the company’s stock valued at $1,086,000 after acquiring an additional 2,101 shares during the period. Baillie Gifford & Co. lifted its holdings in Medpace by 175.6% during the third quarter. Baillie Gifford & Co. now owns 14,876 shares of the company’s stock valued at $4,966,000 after purchasing an additional 9,478 shares in the last quarter. Barclays PLC lifted its holdings in Medpace by 71.9% during the third quarter. Barclays PLC now owns 19,781 shares of the company’s stock valued at $6,603,000 after purchasing an additional 8,275 shares in the last quarter. Oppenheimer Asset Management Inc. boosted its position in shares of Medpace by 6.3% in the third quarter. Oppenheimer Asset Management Inc. now owns 45,473 shares of the company’s stock worth $15,179,000 after purchasing an additional 2,675 shares during the period. Finally, CWA Asset Management Group LLC purchased a new stake in shares of Medpace in the third quarter worth $1,306,000. Hedge funds and other institutional investors own 77.98% of the company’s stock.

Medpace Price Performance

Shares of MEDP opened at $343.38 on Tuesday. The business’s 50 day simple moving average is $342.50 and its 200-day simple moving average is $351.36. Medpace Holdings, Inc. has a 1 year low of $291.15 and a 1 year high of $459.77. The stock has a market capitalization of $10.67 billion, a price-to-earnings ratio of 30.07, a price-to-earnings-growth ratio of 1.79 and a beta of 1.36.

Analysts Set New Price Targets

A number of research analysts recently weighed in on the stock. Truist Financial lowered their target price on shares of Medpace from $415.00 to $397.00 and set a “hold” rating on the stock in a research note on Monday, October 14th. William Blair reaffirmed an “outperform” rating on shares of Medpace in a research note on Tuesday, October 22nd. Redburn Atlantic began coverage on Medpace in a research note on Monday, October 14th. They set a “buy” rating and a $404.00 target price on the stock. TD Cowen dropped their price target on Medpace from $413.00 to $372.00 and set a “buy” rating for the company in a research note on Wednesday, October 23rd. Finally, Baird R W lowered shares of Medpace from a “strong-buy” rating to a “hold” rating in a report on Wednesday, October 23rd. Seven equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to MarketBeat.com, Medpace presently has an average rating of “Hold” and a consensus price target of $381.44.

Medpace Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.